TYPE 2 DIABETES MELLITUS

โœ“ Medically ReviewedENDOCRINEID: MDBTH002ICD-11: 5A11๐Ÿšจ CRITICAL PROTOCOL
๐Ÿ’ก Core Clinical Guidance

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterised by hyperglycaemia resulting from progressive insulin resistance in peripheral tissues combined with a relative deficiency in insulin secretion from pancreatic beta cells. Unlike Type 1 diabetes, endogenous insulin production is preserved but insufficient to overcome insulin resistance.

๐Ÿ“–

Definition

CLINICAL DEFINITION & PATHOPHYSIOLOGY

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterised by hyperglycaemia resulting from progressive insulin resistance in peripheral tissues combined with a relative deficiency in insulin secretion from pancreatic beta cells. Unlike Type 1 diabetes, endogenous insulin production is preserved but insufficient to overcome insulin resistance.

๐Ÿ’Š

Pharmacological Management โ˜…

FIRST-LINE REGIMENS

๐Ÿ’Š Metformin

PREFERRED
500โ€“1000 mgPOTwice daily with mealsLong-term

First-line agent unless contraindicated (eGFR <30, contrast procedures, hepatic impairment); reduces HbA1c by 1โ€“2%

ALTERNATIVE & ESCALATION REGIMENS

๐Ÿ’Š SGLT-2 inhibitors (e.g., Empagliflozin, Dapagliflozin)

10โ€“25 mgPOOnce dailyLong-term

Preferred add-on in patients with established cardiovascular disease or heart failure; also have renal protective effects

๐Ÿ’Š GLP-1 receptor agonists (e.g., Semaglutide, Liraglutide)

VariableSC or POOnce daily or weeklyLong-term

Preferred in patients with obesity or high cardiovascular risk; significant weight-reducing effect

๐Ÿ’Š DPP-4 inhibitors (e.g., Sitagliptin)

100 mgPOOnce dailyLong-term

Weight-neutral; well-tolerated; less potent than SGLT-2i or GLP-1RA

๐Ÿ’Š Insulin (Basal)

0.1โ€“0.2 units/kg/day initiallySCOnce daily (bedtime)Long-term

Used when oral agents fail; titrate based on fasting glucose

ADJUNCTIVE & ADD-ON THERAPIES

๐Ÿ’Š Add second agent if HbA1c remains above target after 3 months on metformin

๐Ÿ’Š Consider cardiovascular/renal benefit when choosing add-on therapy

๐Ÿ’Š Aspirin 75 mg daily in patients with established CVD

๐Ÿ’Š Statin therapy for cardiovascular risk reduction

๐Ÿ’Š ACE inhibitor or ARB if microalbuminuria or hypertension present

SPECIAL PATIENT POPULATIONS
PREGNANCY
  • Insulin is preferred
  • Metformin may be used cautiously
  • Most oral agents are contraindicated
GERIATRICS
  • HbA1c target may be relaxed to 7.5โ€“8.5% to avoid hypoglycaemia
  • Deprescribing complex regimens in frail elderly recommended
PAEDIATRICS
  • Increasing prevalence in children; metformin approved >10 years
  • Lifestyle intervention is primary
RENAL IMPAIRMENT
  • Adjust all renally cleared agents
  • Insulin may require dose reduction
  • SGLT-2 inhibitors contraindicated if eGFR <30
HEPATIC IMPAIRMENT
  • Metformin contraindicated in severe hepatic impairment
  • Monitor closely
CONTRAINDICATIONS & SAFETY CAUTIONS
  • Metformin: avoid in eGFR <30; hold before contrast media
  • SGLT-2 inhibitors: avoid in eGFR <30; risk of diabetic ketoacidosis (DKA) with low carbohydrate diet
  • Sulphonylureas: risk of hypoglycaemia; caution in elderly
  • GLP-1RA: contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
  • Pioglitazone: avoid in heart failure and bladder cancer
โš–๏ธCLINICAL NOTICE & EDUCATIONAL DISCLAIMER

All content in Medobo is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional and local institutional protocols before administering medication or initiating treatment.